Overview

Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia

Status:
Terminated

Trial end date:
2008-04-01

Target enrollment:
0

Participant gender:
All

Summary

To document effectiveness, safety, and tolerability of donepezil in patients with mixed AD/VaD, and to further document the effectiveness, safety, and tolerability of donepezil in patients with VaD. The effects of donepezil on executive functioning, behavior, general cognition, ADLs and global functioning will be assessed.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Donepezil

Criteria

Inclusion Criteria:

- Subjects must meet DSM-IV-TR criteria for the clinical diagnosis of Vascular Dementia
or the clinical diagnosis of dementia due to multiple etiologies.

- Subjects must have a reliable caregiver or family member who agrees to accompany the
subject to all scheduled visits, provide information about the subject as required.

Exclusion Criteria:

- Subjects with any current primary psychiatric diagnosis other than dementia of the
Alzheimer's type or Vascular Dementia.